Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0825 NewAmsterdam Forbion
BioCentury & Getty Images


Seeing path for cholesterol-lowering program, Forbion launches start-up to house former Dezima molecule

Dutch firm reinvests in CETP inhibitor five years after return from Amgen deal

Dutch firm Forbion reinvests in CETP inhibitor five years after receiving a return from its sale to Amgen.

Aug 25, 2020 | 9:46 PM GMT

Five years after reaping a strong return from cholesterol-lowering molecule obicetrapib, Forbion is again investing in the program based on a belief it can serve some dyslipidemia patients where others

Read the full 846 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers